Glasdegib Maleate Patent Expiration

1. Daurismo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148401 PFIZER Benzimidazole derivatives
Jan, 2031

(6 years from now)

US10414748 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431597 PFIZER Benzimidazole derivatives
Jun, 2028

(3 years from now)

US11168066 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(11 years from now)

US11891372 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 21, 2023
Orphan Drug Exclusivity(ODE-224) Nov 21, 2025

NCE-1 date: 21 November, 2022

Market Authorisation Date: 21 November, 2018

Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of...

Dosage: TABLET

More Information on Dosage

DAURISMO family patents

Family Patents